Gennex Laboratories Reports FY26 Revenue of Rs 172.74 Crore

Revenue rose 25% to Rs 172.74 crore, while net profit grew 15.8% to Rs 20.98 crore.

Reader Takeaway: Strong revenue growth is tempered by auditor concerns over financial balances and recent regulatory compliance penalties.

What just happened

Gennex Laboratories held its Annual General Meeting on September 30, 2026, revealing a robust financial performance alongside significant governance and regulatory disclosures. The company successfully converted 1.55 crore warrants into equity shares, bringing in Rs 17.14 crore from promoters.

Why this matters

The financial results show a strong scaling of operations. However, the Independent Auditor has issued a qualification regarding the absence of external confirmations for various financial balances. The management has confirmed that the impact of these balances is currently unascertained, but they are initiating the rollout of 'Transaction Traceability Software' to strengthen internal controls.

Regulatory and Legal Update

The company faced BSE penalties totaling Rs 53.8 lakh due to delays in securing trading approvals for equity shares issued via warrant conversion. A waiver application for these fines is currently pending. Additionally, the company is managing several legacy tax disputes spanning from assessment years 2001-02 to 2019-20.

Corporate Developments

Ms. Khushbu Kachhawa has been appointed as an Independent Director, succeeding Ms. Shilpa Bung, who resigned in February 2026. This transition is a key change to the board's composition following the fiscal year's conclusion.

What to track next

Investors should monitor the implementation progress of the new accounting software and the status of the waiver application regarding the BSE penalties. The resolution of long-standing tax litigation remains a significant item for long-term cash flow clarity.